- Home
- CALX vs PTGX Comparison
CALX vs PTGX Comparison
Compare CALX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- PTGX
- Stock Information
- Founded
- CALX 1999
- PTGX 2006
- Country
- CALX United States
- PTGX United States
- Employees
- CALX N/A
- PTGX N/A
- Industry
- CALX Telecommunications Equipment
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CALX Consumer Discretionary
- PTGX Health Care
- Exchange
- CALX Nasdaq
- PTGX Nasdaq
- Market Cap
- CALX 2.9B
- PTGX 3.3B
- IPO Year
- CALX 2010
- PTGX 2016
- Fundamental
- Price
- CALX $53.93
- PTGX $51.25
- Analyst Decision
- CALX Strong Buy
- PTGX Strong Buy
- Analyst Count
- CALX 5
- PTGX 9
- Target Price
- CALX $48.20
- PTGX $67.11
- AVG Volume (30 Days)
- CALX 605.4K
- PTGX 1.0M
- Earning Date
- CALX 07-21-2025
- PTGX 08-05-2025
- Dividend Yield
- CALX N/A
- PTGX N/A
- EPS Growth
- CALX N/A
- PTGX N/A
- EPS
- CALX N/A
- PTGX 0.86
- Revenue
- CALX $825,450,000.00
- PTGX $207,801,000.00
- Revenue This Year
- CALX $10.66
- PTGX N/A
- Revenue Next Year
- CALX $9.99
- PTGX $47.15
- P/E Ratio
- CALX N/A
- PTGX $59.19
- Revenue Growth
- CALX N/A
- PTGX N/A
- 52 Week Low
- CALX $28.61
- PTGX $32.50
- 52 Week High
- CALX $54.07
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- CALX 78.91
- PTGX 45.80
- Support Level
- CALX $51.33
- PTGX $49.86
- Resistance Level
- CALX $53.66
- PTGX $57.24
- Average True Range (ATR)
- CALX 1.11
- PTGX 2.06
- MACD
- CALX 0.37
- PTGX -0.78
- Stochastic Oscillator
- CALX 98.23
- PTGX 16.14
About CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.